Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs. In the discovery of PCSK9/LDLR (low-density lipoprotein receptor) protein-protein interaction (PPI) impairing small molecules, a total of 47 phenylbenzo[...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fahui, Zhang, Lihui, Feng, Jinhong, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307114/
https://www.ncbi.nlm.nih.gov/pubmed/35854672
http://dx.doi.org/10.1080/14756366.2022.2101645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307114/
https://www.ncbi.nlm.nih.gov/pubmed/35854672
http://dx.doi.org/10.1080/14756366.2022.2101645

Ejemplares similares